OVCAR-3 Cells

Categories: Reproductive system cancer cell lines Description: OVCAR-3 cells are a human ovarian cancer cell line established from the malignant ascites of a 60-year-old Caucasian female patient with progressive adenocarcinoma of the ovary, refractory to treatment with cyclophosphamide, adriamycin, and cisplatin. Ovcar 3 cells are used in a wide range of studies including drug resistance, particularly those involving DNA damage response biomarkers, homologous recombination repair, and the overall cell cycle dynamics, cancer cell biology, and gene expression studies. OVCAR-3 cells are epithelial in morphology and have been characterized by their high in vitro growth potential and their ability to form tumors in immunodeficient mice. These cells express several markers characteristic of ovarian carcinoma and have been utilized extensively to study the biology of ovarian cancer. OVCAR-3 cells are known to have a complex karyotype, with numerous chromosomal abnormalities that are typical of high-grade serous ovarian carcinomas. They are estrogen receptor-positive, which is relatively rare among ovarian cancer cell lines, and this feature is exploited in studies focusing on hormonal influences on ovarian cancer progression and treatment. In summary, the OVCAR3 cell line stands as a cornerstone in ovarian cancer research, offering a robust model for studying the complex interplay between hormonal influences, drug resistance, and the genetic underpinnings of high-grade ovarian serous adenocarcinoma. Organism: Human Tissue: Ovary Disease: High grade ovarian serous adenocarcinoma Metastatic Site: Ascites Synonyms: OVCAR-3, Ovcar-3, OVCAR.3, NIH:Ovcar-3, NIH:OVCAR3, NIH-OVCAR-3, NIHOVCAR3, OVCAR3, Ovcar3 Age: 60 years Gender: Female Ethnicity: Caucasian Growth Properties: Adherent Citation: OVCAR3 (Cytion catalog number 300307) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_0465 Receptors Expressed: Androgen, estrogen, progesterone Isoenzymes: G6PD, B, PGM1, 1, PGM3, 1, ES-D, 1, AK-1, 1, GLO-1, 1 Tumorigenic: Yes, in nude mice Ploidy Status: Aneuploid Msi Status: Stable (MSS) Culture Medium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) Supplements: Supplement the medium with 20% FBS and 0.01 mg/mL bovine insulin Dissociation Reagent: Accutase Doubling Time: 40 to 60 hours Subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. Seeding Density: 2 x 104 cells/cm2 Fluid Renewal: 2 to 3 times per week Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 1: 820700a Required Product 3: 860015.0 Required Product 4: 830100.0